Syndrome WHIM (warts, hypogammaglobulinemia, infections and mielocatexis) is a disease dominant immune autosomal congenital characterized by abnormal retention of mature neutrophils in the bone marrow (mielocatexis) with occasional hypogammaglobulinemia associated with an increased risk of bacterial infections and lesions induced susceptibility to the virus human papillomavirus (HPV) (skin warts, genital dysplasia and carcinoma mucosal invasive).
Summary
[ hide ]
- 1 Synonyms
- 2 Prevalence
- 3 Inheritance
- 4 Age of onset or onset
- 5 Epidemiology
- 6 Clinical description
- 7 Etiology
- 8 Diagnostic methods
- 1 Differential diagnosis
- 2 Prenatal diagnosis
- 3 Genetic advice
- 9 Management and treatment
- 10 Forecast
- 11 Sources
Synonyms
- Wart syndrome – hypogammaglobulinemia -infections – myelocatexis
- Wart syndrome – infections – leukopenia – myelocatexis
- WILM
Prevalence
- <1 / 1,000,000
Heritage
- Autosomal dominant or Autosomal recessive or Not applicable
Age of onset or onset
- Childhood, Adolescence , Adulthood
epidemiology
The syndrome WHIM is extremely rare; to date only 65 cases have been registered worldwide. The incidence in France between 1990 and 2006 has been estimated at less than 1 / 4,000,000 births.
Clinical description
The syndrome WHIM has a heterogeneous clinical picture. It usually occurs in early childhood with recurrent bacterial infections including pharyngitis , sinusitis , otitis , meningitis, and pneumonia.and that they respond well to antibiotics. The response to vaccination is poor; When measured by titration of specific antibodies, a low initial response is observed followed by the rapid disappearance of said specific antibodies. Over 80% of patients develop, by age 30, generalized HPV-induced warts that are often difficult to treat and usually begin on the hands and feet. 25% develop anogenital acuminate condyloma that can lead to intravenous HPV-induced multifocal dysplastic lesions and invasive genital cancer. Tetralogy of Fallot has been observed in approximately 1/4 of the cases.
Etiology
WHIM syndrome is caused by heterozygous gain-of-function mutations in the CXCR4 (2q21) gene that encodes a chemokine receptor that is expressed in mature leukocytes and that is implicated in signal transduction pathways that control adhesion and settlement. of bone marrow cells , myelopoiesis and lymphopoiesis. Mutations cause prolonged activation of the receptor, which leads to retention of neutrophils and other leukocytes in the bone marrow.
Diagnostic methods
Diagnosis is based on evaluation of clinical signs in conjunction with the following laboratory findings: Blood cell counts typically show (except in acute infection ) neutropenia , lymphopenia, and monocytopenia leading to severe panleukopenia with normal levels of hemoglobin and platelets; serum immunoglobulin levels G, A and M show slight hypogammaglobulinemia in almost all cases; and bone marrow aspirates reveal myelocatexis. Molecular genetic analysis of CXRC4 confirms the diagnosis.
Differential diagnosis
The differential diagnosis of diseases involving mielocatexis includes neutropenia severe congenital autosomal dominant severe congenital neutropenia caused by autosomal recessive deficiency G6PC3, verruciform epidermodysplasia and monocytopenia with susceptibility to infection (see these terms).
Prenatal diagnosis
A prenatal test can be performed by amniocentesis or chorionic villus sampling if there is a family history.
Genetic advice
The syndrome WHIM is usually transmitted as an autosomal dominant trait, but cases have also been described autosomal recessive or sporadic.
Management and treatment
Currently, the treatment is symptomatic. The therapy replacement with immunoglobulins and prophylactic antibiotics can prevent infection. A treatment with granulocyte colony stimulating factor (GCSF) can also be used. Both standard (cauterization, laser therapy) and more aggressive methods (surgical removal, interferon, cidofovir, imiquimod) appear to be largely ineffective for the treatment of HPV-induced lesions. A clinical trial with a CXCR4 antagonist (Plerixaflor) is currently underway in the USA. UU . which, shortly, will also start in Europe . Published cases suggest that the HPV vaccine may limit the incidence ofinfection .
Forecast
People affected by WHIM can lead a relatively normal life in adulthood. Major risk factors include HPV-induced intractable multifocal dysplastic lesions and invasive genital cancer, as well as liver failure. By age 40, the risk of developing cancer is close to 30%.
